Quick Facts
Which of the following is another name for fibroids?
myomas
leiomyomas
leiomyomata uteri
all of the above

Product Information

Supporting you with as much information as possible about your Lupron Depot® treatment is important. Here you can access Patient Product Information, a Fibroids Brochure in both English and Spanish, and complete Prescribing Information.

Patient Product Information

Patient Product Information can help you gain a better understanding of treatment with Lupron Depot, including how it is administered and how it is used to treat anemia due to fibroids. Click on a link below to launch the Patient Product Information in a printer-friendly window.

Fibroids Brochure

This brochure was created to help answer your questions about fibroids and treatment with Lupron Depot 3.75 mg and -3 Month 11.25 mg. Click on the link below to launch the brochure in a printer-friendly window.

Note: This patient education brochure is not intended to be a substitute for information provided to you by your healthcare provider or provided to your healthcare provider by TAP Pharmaceuticals Inc. You should discuss with your healthcare provider any questions you have about the diagnosis and treatment of fibroids.

Prescribing Information

For complete prescribing information for Lupron Depot, click on a link below to launch the Lupron Depot package insert in a printer-friendly window. If you have any questions, please ask your doctor.

Choose the dosage you wish to learn more about:

You will need Adobe® Reader® to display patient product information, prescribing information, and the brochures. To download the free reader, click on the icon below.


 

Other Important Information:

Lupron Depot® (3.75 mg and - 3 Month 11.25 mg), in combination with iron, is used for the preoperative treatment of anemia associated with uterine fibroids. Most common side effects with Lupron Depot are generally those related to low estrogen levels, including hot flashes, headaches, and vaginal dryness. A small amount of bone loss (average 2.7% at month three) may also occur during therapy.

For further information about Lupron Depot, please see the complete Prescribing Information, as well as the Patient Product Information.